Recent Updates
Recently added Catalysts
HOWL Positive Sentiment

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Wednesday, November 15, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Werewolf Therapeutics, a biopharmaceutical company, has reported its financial results for the third quarter of 2023. The company specializes in developing conditionally activated therapeutics aimed at enhancing the immune response in cancer treatment. The report reflects ongoing business updates and financial performance as of September 30, 2023.
Price reaction · baseline $2.27 (2023-11-15T14:46:00.000Z) · hit during market hours · clean, no other HOWL news in the window
day 0 close · peak
-3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Werewolf Therapeutics is pioneering innovative therapeutics.
  • The company is focused on stimulating the immune system for cancer treatment.
  • The financial update indicates growth and business development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors

Full Press Release Details

WATERTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for the third quarter ended September 30, 2023.

Frequently Asked Questions

What did Werewolf Therapeutics report for Q3 2023?

Werewolf Therapeutics reported its financial results and business updates for Q3 2023.

What is the focus of Werewolf Therapeutics?

The company focuses on developing therapeutics that activate the immune system for cancer treatment.

When does the financial quarter end for Werewolf?

The financial quarter for Werewolf Therapeutics ended on September 30, 2023.

ShareAdd on Google
Tags: HOWL Viatris Investor Conferences Healthcare Werewolf Therapeutics financial results cancer treatment biopharmaceuticals
Last updated: Nov 15, 2023

Biotech snapshot

Cash runway
$22M liquidity · $0M/mo burn
Low dilution risk
Lead asset
WTX-330Phase 1
Advanced or Metastatic Solid Tumors →

Catalyst track record

+25%
best trade around HOWL's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for HOWL.

See every catalyst's timing & PoA →